Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Cyfendus - A dual-dose anthrax vaccine for post-exposure prevention of anthrax
Drug Insights
5 min read
Cyfendus - A dual-dose anthrax vaccine for post-exposure prevention of anthrax
14 August 2023
Anthrax Vaccine Adsorbed, Adjuvanted, com-mercially known as CYFENDUS, is a preventive vaccine targeting TLR9.
Read →
Progress in the Research and Development of cGAS-STING Drug Targets
Progress in the Research and Development of cGAS-STING Drug Targets
14 August 2023
The cGAS-STING signaling pathway is a cytoplasmic DNA sensing pathway that plays a critical role in innate immune responses.
Read →
Deciphering the cGAS-STING Pathway: Unlocking the Secrets of Aging and Inflammation
Advanced Tech.
6 min read
Deciphering the cGAS-STING Pathway: Unlocking the Secrets of Aging and Inflammation
11 August 2023
cGAS-STING is a molecular signaling pathway involving two proteins, cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING).
Read →
Positive Results of Phase III Clinical Trials for Bavarian's Chikungunya Virus Vaccine PXVX0317
Latest Hotspot
3 min read
Positive Results of Phase III Clinical Trials for Bavarian's Chikungunya Virus Vaccine PXVX0317
10 August 2023
On August 8, 2023, Bavarian Nordic announced positive top-line results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of its Chikungunya virus candidate vaccine, CHIKV VLP (PXVX0317), in adults and adolescents aged 12 to 64.
Read →
Roche Clinical Trial Phase I of Oral Cyclic Peptide KRAS G12D Inhibitor
Roche Clinical Trial Phase I of Oral Cyclic Peptide KRAS G12D Inhibitor
10 August 2023
The KRAS G12D mutation affects approximately 180,000 patients in the United States and Europe, showing an incidence rate about 2.5 times higher compared to the KRAS G12C mutation.
Read →
Vistagen's new drug, Fasedienol, reaches Phase 3 clinical trial endpoint, alleviating social anxiety disorder
Latest Hotspot
3 min read
Vistagen's new drug, Fasedienol, reaches Phase 3 clinical trial endpoint, alleviating social anxiety disorder
10 August 2023
On August 8, 2023, Vistagen announced the positive top-line results of the PALISADE-2 Phase 3 clinical trial, which assessed the efficacy and safety of its investigational fasedienol (PH94B, Aloradine) nasal spray in adult patients with social anxiety disorder (SAD).
Read →
Expanding the Horizons of CAR T Therapy Beyond Cancer Treatment: Part II
Advanced Tech.
5 min read
Expanding the Horizons of CAR T Therapy Beyond Cancer Treatment: Part II
10 August 2023
The success of CAR-T in hematologic malignancies lays the foundation for treating solid tumors, and oncology results will provide crucial knowledges for converting CAR-T to other diseases.
Read →
The Discovery Process of TAK-279 and the Deep Logic Behind its Acquisition by Takeda
Drug Insights
9 min read
The Discovery Process of TAK-279 and the Deep Logic Behind its Acquisition by Takeda
9 August 2023
the approved dose for BMS's Deucravacitinib treatment of psoriasis is 6mg QD, whereas the estimated dose for TAK279 clinical treatment of psoriasis is over 30mg QD. Why does TAK279 have BIC potential?
Read →
Expanding the Horizons of CAR T Therapy Beyond Cancer Treatment: Part I
Advanced Tech.
6 min read
Expanding the Horizons of CAR T Therapy Beyond Cancer Treatment: Part I
9 August 2023
As research has progressed, CAR-T’s efficacy has been found to extend beyond cancer with great potential in treating autoimmunity, infections, fibrosis, aging-related diseases and more.
Read →
The Discovery Process of a Novel STAT6 Inhibitor
The Discovery Process of a Novel STAT6 Inhibitor
9 August 2023
STAT6 is essential for IL-4 and IL-13 signal transduction, but it is downstream of the JAK/STAT pathway and is not utilized by other cytokines and growth factors.
Read →
What is the Prospect of Lilly's BTK Inhibitor LOXO305?
Valuable Targets
10 min read
What is the Prospect of Lilly's BTK Inhibitor LOXO305?
8 August 2023
While paying attention to the third-generation non-covalent BTK inhibitors, we can also consider other approaches to solve drug resistance.
Read →
Can JAK3 Replicate TYK2's Success?
Can JAK3 Replicate TYK2's Success?
8 August 2023
Among the JAK Family Members, JAK3, which Only Regulates a Narrow Spectrum of γc Cytokines, Emerges as a Potential Ideal Target.
Read →